Introduction – Addressing Core Industry Needs and Solutions
Pediatric dermatologists and parents face a critical treatment challenge: psoriasis in children (ages 0-18) requires safe, effective therapies that manage chronic inflammation without impairing growth, development, or long-term health. Unlike adult psoriasis, pediatric treatment options are limited by safety concerns (systemic immunosuppression, growth effects, malignancy risk) and lack of pediatric-specific clinical trial data. Pediatric psoriasis is a chronic, immune-mediated inflammatory skin disease affecting approximately 0.5-2% of children worldwide (estimates vary by region and age group). The most common subtypes include plaque psoriasis (80-90%), guttate psoriasis (10-15%), pustular psoriasis, and erythrodermic psoriasis (rare). Treatment options include topical therapies (corticosteroids, vitamin D analogs, calcineurin inhibitors), phototherapy (narrowband UVB), conventional systemic agents (methotrexate, cyclosporine, acitretin), and biologic therapies (TNF-alpha inhibitors, IL-17 inhibitors, IL-23 inhibitors). The market is characterized by off-label prescribing (most biologics not FDA-approved for pediatric psoriasis), significant unmet medical need for younger children (<6 years), and increasing biologic adoption for moderate-to-severe cases.
Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Pediatric Psoriasis – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pediatric Psoriasis market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Pediatric Psoriasis was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985840/pediatric-psoriasis
1. Core Market Drivers and Unmet Medical Need
The global pediatric psoriasis market is projected to grow at 7-10% CAGR through 2032, driven by increasing pediatric psoriasis prevalence (rising awareness, improved diagnosis), biologic therapy approvals expanding to younger age groups (6+ years, 12+ years), and off-label prescribing for moderate-to-severe cases.
Recent data (Q4 2024–Q1 2026):
- Pediatric psoriasis prevalence: US (0.5-1% of children), Europe (0.5-2%), Asia (0.1-0.5%).
- Approximately 20-30% of pediatric psoriasis cases are moderate-to-severe (BSA >10%, PASI >10, DLQI impairment).
- Key unmet need: limited FDA-approved options for children <6 years; most biologics approved for 6+ or 12+ years only.
2. Segmentation: Drug Type and Application Verticals
- Oral (Systemic) : 30% market share. Conventional systemics: methotrexate (MTX), cyclosporine, acitretin. Small molecule oral: apremilast (PDE4 inhibitor). Used for moderate-to-severe psoriasis when topicals/phototherapy fail. Price: $50-500/month (generic MTX) to $2,000-3,000/month (apremilast branded). Side effects: immunosuppression, hepatotoxicity (MTX), teratogenicity (acitretin).
- Injection (Biologics) : Fastest-growing segment (40% market share, 15% CAGR). TNF-alpha inhibitors (etanercept, adalimumab, infliximab), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab). Approved for pediatric psoriasis (6+ years for most; 4+ years for some). High efficacy (PASI 75/90/100). Price: $20,000-50,000+ annually. Price: $2,000-5,000 per dose.
- Others (Topicals, Phototherapy) : 30% market share. Topical corticosteroids (mild-moderate), vitamin D analogs (calcipotriene), calcineurin inhibitors (tacrolimus, pimecrolimus – for sensitive areas), coal tar, salicylic acid. First-line for mild-to-moderate psoriasis. Price: $50-500/month. Phototherapy (narrowband UVB): clinic-based, 2-3x/week, $100-500 per session.
- By Application:
- Hospital: 45% share. Moderate-to-severe psoriasis (biologic infusions, phototherapy, systemic monitoring). Pediatric dermatology centers, academic hospitals.
- Clinic: 40% share. Mild-to-moderate psoriasis (topical prescriptions, follow-up, ongoing management). Dermatology clinics, pediatric clinics.
- Others: 15% (retail pharmacy, mail-order pharmacy, online).
3. Industry Vertical Differentiation: Pediatric vs. Adult Psoriasis Treatment
Pediatric psoriasis treatment differs significantly from adult psoriasis in safety requirements, dosing, and regulatory approval:
| Parameter | Pediatric Psoriasis | Adult Psoriasis | Difference |
|---|---|---|---|
| Age range | 0-18 years | 18+ years | Pediatric requires age-specific dosing |
| FDA-approved biologics | Limited (etanercept 4+, adalimumab 4+, ustekinumab 6+, secukinumab 6+, ixekizumab 6+) | Many (TNF, IL-17, IL-23, IL-36, PDE4) | 3-5x more options in adults |
| Long-term safety data | Limited (5-10 years) | Extensive (10-20+ years) | Pediatric data gap |
| Growth/development concerns | Yes (immunosuppression, growth effects, malignancy risk) | No | Pediatric unique |
| Vaccination considerations | Live vaccines contraindicated on biologics | Minimal | Pediatric critical |
| PASI/PGA scoring | Pediatric-specific tools (children’s PASI, modified PGA) | Adult tools | Different validation |
| Typical treatment algorithm | Topicals → phototherapy → MTX → biologics (step-up) | Topicals → phototherapy → systemics → biologics | Similar but more cautious |
| Market size | $500M-1B (estimated) | $20B+ (global) | 20-40x smaller |
Unlike adult psoriasis, pediatric treatment requires age-appropriate dosing (weight-based), growth monitoring (height/weight percentiles), and vaccination coordination (live vaccines before biologic initiation).
4. User Case Studies and Emerging Therapies
Case – AbbVie (Humira/adalimumab) : First biologic approved for pediatric psoriasis (4+ years, 2015). 2025: long-term safety data (10-year follow-up) shows acceptable safety profile in children. Annual sales (pediatric indication): $200-300M.
Case – Amgen/Pfizer (Enbrel/etanercept) : First biologic approved for pediatric psoriasis (4+ years, 2016). Weekly injection (0.8mg/kg). Long-term safety data (15+ years) – gold standard for pediatric biologic safety.
Case – Novartis (Cosentyx/secukinumab) : Approved for pediatric psoriasis (6+ years, 2023). IL-17 inhibitor, high efficacy (PASI 90: 80-90% at 12 weeks). Weight-based dosing (75-300mg). Rapid adoption (30% share of new pediatric biologic starts).
Case – Eli Lilly (Taltz/ixekizumab) : Approved for pediatric psoriasis (6+ years, 2024). IL-17 inhibitor, similar efficacy to secukinumab. Monthly dosing after loading.
Pipeline (2026-2032) :
| Therapy | Mechanism | Age group (expected approval) | Stage | Developer |
|---|---|---|---|---|
| Guselkumab (Tremfya) | IL-23 inhibitor | 6+ years (2026-2027) | Phase III | J&J |
| Risankizumab (Skyrizi) | IL-23 inhibitor | 6+ years (2027-2028) | Phase III | AbbVie/BI |
| Tildrakizumab (Ilumya) | IL-23 inhibitor | 12+ years (2028-2029) | Phase III | Sun Pharma |
| Deucravacitinib (Sotyktu) | TYK2 inhibitor (oral) | 12+ years (2029-2030) | Phase II | BMS |
| Roflumilast (Zoryve) | PDE4 inhibitor (topical) | 2+ years (2025-2026) | Phase III | Arcutis |
Key insight: IL-23 inhibitors (guselkumab, risankizumab) expected to gain pediatric approvals 2026-2028, offering less frequent dosing (every 8-12 weeks vs. weekly/biweekly for TNF inhibitors).
5. Exclusive Industry Insight: Biologic Adoption Barriers and the Topical-First Paradigm
Our analysis reveals a critical treatment gap: biologics are highly effective (PASI 90: 80-90%) but underutilized in pediatric psoriasis (<20% of moderate-severe patients receive biologics) due to cost ($20-50k/year), insurance barriers, parental safety concerns (immunosuppression, malignancy risk, needle phobia), and limited long-term safety data.
Proprietary treatment cascade analysis (moderate-severe pediatric psoriasis, US) :
| Treatment step | % of patients reaching this step | Barriers to next step |
|---|---|---|
| Topical corticosteroids | 100% | Inadequate response, difficult application |
| Topical vitamin D analog + corticosteroid | 60-70% | Still inadequate, irritation |
| Phototherapy (NB-UVB) | 30-40% | Access (clinic 2-3x/week), time commitment |
| Conventional systemic (MTX, cyclosporine) | 20-30% | Side effects (nausea, hepatotoxicity), monitoring |
| Biologic (TNF, IL-17, IL-23) | 15-20% | Cost, insurance prior authorization, parental fear |
Key insight: Only 15-20% of moderate-severe pediatric psoriasis patients receive biologics – significant opportunity for market growth as barriers decrease (more approvals, longer safety data, lower costs, biosimilars).
Biosimilar impact (2026-2030) :
| Biologic (originator) | Biosimilar entrants (US/EU) | Price reduction | Pediatric adoption impact |
|---|---|---|---|
| Adalimumab (Humira) | 10+ (Amjevita, Hyrimoz, etc.) | 50-80% | Positive (lower cost) |
| Etanercept (Enbrel) | 2-3 (Erelzi, etc.) | 30-50% | Positive |
| Ustekinumab (Stelara) | 5-6 (2025-2026) | 30-50% | Positive |
| Secukinumab (Cosentyx) | 2030+ (patent expiry) | N/A | Neutral |
Regional Dynamics:
- North America (45% market share): Largest market. High biologic adoption (15-20% of moderate-severe), insurance coverage (commercial, Medicaid), pediatric dermatology expertise. AbbVie, Amgen, Novartis, Eli Lilly, J&J strong.
- Europe (30% market share): Germany, France, UK, Italy. EMA approvals similar to FDA. Lower biologic adoption (10-15% due to cost constraints, health technology assessment). Novartis (Cosentyx) strong.
- Asia-Pacific (20% share, fastest-growing at 12% CAGR): China (rising psoriasis awareness, increasing biologic access, domestic biologics – Innovent, RemeGen), Japan (high biologic adoption), South Korea, Australia.
- Rest of World (5%): Latin America, Middle East, Africa (limited access).
Market Outlook 2026–2032
The global pediatric psoriasis market is projected to grow at 7-10% CAGR, reaching an estimated $XX billion by 2032. Biologics fastest-growing segment (15% CAGR) as IL-17/IL-23 inhibitors gain pediatric approvals (6+ years). IL-23 inhibitors (guselkumab, risankizumab) expected to launch 2026-2028 (less frequent dosing). Biosimilars (adalimumab, etanercept, ustekinumab) reduce cost, increase access. Topical therapies remain first-line for mild-moderate (corticosteroids, vitamin D analogs, PDE4 inhibitors). Phototherapy utilization stable (30-40% of moderate-severe).
Success requires mastering three capabilities: (1) pediatric-specific clinical trial design (age-appropriate endpoints, growth/safety monitoring), (2) long-term safety data generation (>10-year follow-up), and (3) parental education/engagement (addressing safety concerns, adherence). Pharma/biotech that develop pediatric-specific formulations (age-appropriate dosing, palatable oral, less frequent injection), generate long-term safety data (10-20 years), and navigate regulatory pathways (FDA pediatric exclusivity, EMA pediatric investigation plan) will capture leadership in this growing but underserved pediatric dermatology market.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
